RxDoctor Payments Data

Renny Varghese, MD

Family Medicine · League City, TXNPI 1265967806

Payments from drug & device makers

$2,142in general payments, 2019–2025

Across 23 payments — averaging $93.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$879
  • AbbVie$295
  • Lilly USA, LLC$231
  • Medtronic$229
  • Abbott$124
  • Pharmacosmos Therapeutics Inc.$124
  • plus $260 from 5 others

What the payments were for

  • Food & beverage$2,142100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,142 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,573
Medicare patients
220
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$187,156
MounjaroTirzepatide126$160,887
FarxigaDapagliflozin Propanediol50$62,037
EliquisApixaban32$40,850
RybelsusSemaglutide33$38,399
JardianceEmpagliflozin32$27,053
UbrelvyUbrogepant15$19,312
XareltoRivaroxaban20$17,650
LinzessLinaclotide15$17,348
QuliptaAtogepant13$14,246
Repatha SureclickEvolocumab16$11,881
Tresiba Flextouch U-100Insulin Degludec14$10,285
PremarinEstrogens, Conjugated13$5,544
Repatha SyringeEvolocumab11$5,085
Dexlansoprazole DrDexlansoprazole17$3,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$879$225,556168 claims
Lilly USA, LLCMounjaro$231$160,887126 claims
AbbVieUbrelvy, Linzess, Qulipta$295$50,90643 claims
PfizerEliquis, Premarin$21$46,39445 claims
Boehringer IngelheimJardiance$20$27,05332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in League City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →